Telavancin in Experimental Murine Pneumococcal Pneumonia
Telavancin in Experimental Murine Pneumococcal Pneumonia作者机构：Department of Health Sciences Research Mayo Clinic Division of Biomedical Statistics and Informatics Rochester US Department of Laboratory Medicine and Pathology Division of Clinical Microbiology Rochester US Department of Medicine Division of Infectious Diseases Rochester US
出 版 物：《Journal of Immune Based Therapies, Vaccines and Antimicrobials》 (基于免疫的治疗疫苗和抗菌期刊（英文）)
年 卷 期：2012年第1卷第2期
页 面：15-19页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Telavancin Murine Pneumonia
摘 要：We determined whether telavancin is as active in experimental immunocompetent murine pneumococcal pneumonia as is vancomycin or ceftriaxone. Experimental murine pneumonia was established by intratracheal administration of Streptococcus pneumoniae. Four groups of animals were studied, untreated and treated with vancomycin (110 mg/kg, bid, SQ), telavancin (40 mg/kg, bid, SQ), or ceftriaxone (50 mg/kg, bid, SQ) for 2 days. The untreated animals had a mean of 6.54 ± 0.82 log10 cfu/g lung. The vancomycin-, telavancin-, and ceftriaxone-treated animals had means of 2.01 ± 0.02, 2.00 ± 0.00, and 2.00 ± 0.01 log10 cfu/g lung, respectively (p-values 0.0001 for each treatment group versus the untreated group). In the model studied, telavancin was as active as vancomycin and ceftriaxone in treating experimental pneumococcal pneumonia in mice.
维普期刊数据库